cat > /home/daytona/workspace/nmj-ppt/nmj.js << 'ENDOFSCRIPT' const pptxgen = require("pptxgenjs"); const pres = new pptxgen(); pres.layout = 'LAYOUT_16x9'; pres.title = 'Neuromuscular Junction: Anatomy, Physiology & Metabolism'; const C = { bg: "FFFFFF", navy: "0D2B4E", blue: "1565C0", teal: "00838F", grey: "546E7A", ltgrey: "ECEFF1", accent: "F57F17", white: "FFFFFF", }; function accentBar(slide) { slide.addShape(pres.ShapeType.rect, { x:0,y:0,w:0.08,h:5.625, fill:{color:C.blue}, line:{color:C.blue} }); } function headBar(slide, title) { slide.addShape(pres.ShapeType.rect, { x:0.08,y:0,w:9.92,h:0.9, fill:{color:C.ltgrey}, line:{color:C.ltgrey} }); slide.addText(title, { x:0.25,y:0,w:9.6,h:0.9, fontSize:20,bold:true,color:C.navy,fontFace:"Calibri",align:"left",valign:"middle",margin:0 }); } function sectionDivider(slide, title, num) { slide.addShape(pres.ShapeType.rect, { x:0,y:0,w:10,h:5.625, fill:{color:C.navy}, line:{color:C.navy} }); slide.addShape(pres.ShapeType.rect, { x:0,y:4.8,w:10,h:0.825, fill:{color:C.blue}, line:{color:C.blue} }); slide.addText(num, { x:0.4,y:0.4,w:2,h:1.5, fontSize:72,bold:true,color:C.blue,fontFace:"Calibri",align:"left",transparency:40 }); slide.addText(title, { x:0.5,y:1.9,w:9,h:2, fontSize:32,bold:true,color:C.white,fontFace:"Calibri",align:"left",valign:"middle",wrap:true }); } function bullets(slide, heading, items, note) { accentBar(slide); headBar(slide, heading); const its = items.map((b,i)=>({ text:b, options:{ bullet:{type:"bullet",code:"2022"}, color:b.startsWith("→")?C.teal:C.grey, fontSize:b.startsWith("→")?13.5:15, fontFace:"Calibri", breakLine:i arr.map((b,i)=>({ text:b, options:{ bullet:{type:"bullet",code:"2022"}, color:C.grey, fontSize:14, fontFace:"Calibri", breakLine:i{ const col=i%cols, row=Math.floor(i/cols); const x=0.25+col*(bW+0.15), y=0.95+row*(bH+0.15); slide.addShape(pres.ShapeType.rect, { x,y,w:bW,h:bH, fill:{color:b.color||C.ltgrey}, line:{color:b.color||C.ltgrey} }); slide.addText(b.title, { x:x+0.1,y:y+0.05,w:bW-0.2,h:0.42, fontSize:13.5,bold:true,color:C.navy,fontFace:"Calibri",wrap:true }); slide.addText(b.text, { x:x+0.1,y:y+0.47,w:bW-0.2,h:bH-0.57, fontSize:12.5,color:C.grey,fontFace:"Calibri",wrap:true,valign:"top" }); }); } function table(slide, heading, headers, rows) { accentBar(slide); headBar(slide, heading); const data = [ headers.map(h=>({ text:h, options:{bold:true,color:C.white,fill:C.navy,fontSize:13,fontFace:"Calibri"} })), ...rows.map((row,ri)=>row.map(cell=>({ text:cell, options:{color:C.grey,fill:ri%2===0?C.ltgrey:C.white,fontSize:12,fontFace:"Calibri"} }))) ]; slide.addTable(data, { x:0.25,y:1.0,w:9.5, colW:Array(headers.length).fill(9.5/headers.length), rowH:0.43, border:{pt:0.5,color:"D0D0D0"} }); } // ── SLIDE 1 — Title { const s=pres.addSlide(); s.addShape(pres.ShapeType.rect,{x:0,y:0,w:10,h:5.625,fill:{color:C.bg},line:{color:C.bg}}); s.addShape(pres.ShapeType.rect,{x:0,y:0,w:0.35,h:5.625,fill:{color:C.blue},line:{color:C.blue}}); s.addShape(pres.ShapeType.rect,{x:0,y:4.4,w:10,h:1.225,fill:{color:C.navy},line:{color:C.navy}}); s.addText("Neuromuscular Junction\nAnatomy, Physiology & Metabolism",{x:0.6,y:0.9,w:9,h:2.2,fontSize:34,bold:true,color:C.navy,fontFace:"Calibri",align:"left",valign:"middle",wrap:true}); s.addText("Structure • Function • Neurotransmission • Clinical Correlates",{x:0.6,y:3.05,w:9,h:0.7,fontSize:17,color:C.teal,fontFace:"Calibri",align:"left"}); s.addText("Sources: Ganong's 26e | Miller's Anesthesia 10e | Katzung's Pharmacology 16e | Goodman & Gilman",{x:0.6,y:4.6,w:9,h:0.45,fontSize:10,color:C.white,italic:true,fontFace:"Calibri",align:"left"}); } // ── SLIDE 2 — Outline { const s=pres.addSlide(); bullets(s,"Presentation Outline",[ "Section 01 — Introduction & Overview of the NMJ", "Section 02 — Gross Anatomy: Motor Unit & Axon Terminal", "Section 03 — Microanatomy: Three Zones of the NMJ", "Section 04 — Presynaptic Ultrastructure & Active Zones", "Section 05 — Synaptic Cleft, Basal Lamina & Postsynaptic Membrane", "Section 06 — Acetylcholine Synthesis, Storage & Vesicle Pools", "Section 07 — SNARE Proteins & Exocytosis", "Section 08 — Calcium in Neuromuscular Transmission", "Section 09 — Nicotinic AChR: Structure, Activation & States", "Section 10 — Endplate Potential, Safety Factor & MEPPs", "Section 11 — Acetylcholinesterase, Choline Recycling & Metabolism", "Section 12 — NMJ Development, Maintenance & Plasticity", "Section 13 — Neuromuscular Blocking Drugs", "Section 14 — NMJ Disorders (MG, LEMS, CMS, Botulism)", "Section 15 — Drug Targets Summary | Section 16 — Key Points", ]); } // ── SLIDE 3 — Section 01 { const s=pres.addSlide(); sectionDivider(s,"Introduction & Overview","01"); } // ── SLIDE 4 — What is the NMJ? { const s=pres.addSlide(); bullets(s,"What is the Neuromuscular Junction?",[ "Specialized synapse between a motor neuron axon terminal and a skeletal muscle fiber.", "Converts an electrical nerve impulse into a chemical signal → triggers muscle contraction.", "Also termed the myoneural junction or motor end plate region.", "Key components: presynaptic nerve terminal, synaptic cleft (~50–70 nm), postsynaptic motor endplate.", "Primary neurotransmitter: acetylcholine (ACh), acting on nicotinic cholinergic (NM) receptors.", "Critical for all voluntary movement; disorders here cause profound weakness or paralysis.", "Site of action of clinical agents: neuromuscular blocking drugs, AChE inhibitors, botulinum toxin.", ],"Source: Ganong's Review of Medical Physiology, 26th Ed."); } // ── SLIDE 5 — Historical Milestones { const s=pres.addSlide(); bullets(s,"Historical Milestones in NMJ Research",[ "1906 — Sir Charles Sherrington coins 'synapse'; motor unit concept established.", "1921 — Otto Loewi demonstrates chemical neurotransmission (ACh at heart).", "1936 — Loewi & Dale awarded Nobel Prize for chemical neurotransmission.", "1950s — Bernard Katz describes quantal ACh release using intracellular microelectrodes.", "1960s — Electron microscopy reveals NMJ ultrastructure: vesicles, active zones, junctional folds.", "1970s–80s — Nicotinic AChR isolated, cloned, and fully sequenced (Numa et al.).", "1993–2000 — SNARE hypothesis established; synaptobrevin, syntaxin, SNAP-25 characterized.", "2001–present — Live imaging of single vesicle fusion; agrin/MuSK/LRP4 signaling pathway mapped.", ]); } // ── SLIDE 6 — Section 02 { const s=pres.addSlide(); sectionDivider(s,"Gross Anatomy: The Motor Unit","02"); } // ── SLIDE 7 — Motor Unit { const s=pres.addSlide(); bullets(s,"The Motor Unit",[ "Definition: one alpha motor neuron + all skeletal muscle fibers it innervates.", "Motor neuron origin: anterior horn cells (spinal cord) or brainstem motor nuclei.", "The axon travels in peripheral nerve; loses myelin sheath near the endplate zone.", "Each axon branches into multiple terminal boutons — one bouton per muscle fiber.", "Each muscle fiber receives exactly ONE motor neuron terminal (single innervation).", "Small motor units (extraocular, intrinsic hand): 5–10 fibers → fine motor control.", "Large motor units (quadriceps, gastrocnemius): 1000–2000 fibers → force generation.", "Motor unit recruitment follows Henneman's size principle: smaller units recruited first.", ],"Source: Ganong's Review of Medical Physiology, 26th Ed."); } // ── SLIDE 8 — Axon Terminal Approach { const s=pres.addSlide(); bullets(s,"Axon Terminal: Myelination & Branching",[ "Motor axons are myelinated Aα fibers; conduction velocity 70–120 m/s.", "Near the NMJ, myelin sheath is lost → bare axon exposed (node of Ranvier-like unmyelinated zone).", "Terminal branches: multiple boutons, each ~1–2 µm diameter.", "Each bouton sits in a primary groove (primary synaptic gutter) in the muscle membrane.", "Schwann cells cap the non-release face of the terminal — trophic support, not insulation.", "Terminal is held in position by the basal lamina and Schwann cell processes.", "Loss of the terminal (axotomy) → muscle denervation → upregulation of fetal nAChRs within 24–48 hours.", "Axonal regrowth is guided back to original junctional sites by basal lamina components.", ]); } // ── SLIDE 9 — Section 03 { const s=pres.addSlide(); sectionDivider(s,"Microanatomy of the NMJ","03"); } // ── SLIDE 10 — Three Zones { const s=pres.addSlide(); boxes(s,"Three Zones of the NMJ",[ {title:"Zone 1: Presynaptic Terminal",text:"Axon bouton. Contains: synaptic vesicles (~50 nm), mitochondria, active zones, P/Q-type Ca²⁺ channels, SNARE proteins (syntaxin, SNAP-25, synaptobrevin).",color:"E3F2FD"}, {title:"Zone 2: Synaptic Cleft",text:"~50–70 nm wide. Filled with basal lamina containing acetylcholinesterase (AChE) anchored via ColQ tail. Also contains agrin, laminin, perlecan.",color:"E8F5E9"}, {title:"Zone 3: Postsynaptic Membrane",text:"Motor endplate with deep junctional folds. nAChRs clustered at fold crests (~10,000/µm²). Voltage-gated Nav1.4 channels in fold troughs. Rapsyn scaffold links nAChRs to cytoskeleton.",color:"FFF8E1"}, ]); } // ── SLIDE 11 — Presynaptic Ultrastructure { const s=pres.addSlide(); bullets(s,"Presynaptic Terminal — Ultrastructure",[ "Mitochondria: very abundant (~50% of terminal volume); provide ATP for synthesis, vesicle cycling, ion pumping.", "Synaptic vesicles: ~50 nm, spherical, clear (small-molecule transmitter); ~200,000–500,000 per terminal.", "Active zones (AZs): electron-dense specializations of presynaptic membrane, ~300 per bouton.", "Voltage-gated Ca²⁺ channels (Cav2.1, P/Q-type): clustered at AZ margins — within 10–20 nm of vesicle docking sites.", "SNARE proteins on plasma membrane: syntaxin-1 and SNAP-25.", "Actin cytoskeleton: scaffolds reserve pool vesicles via synapsin linkages.", "Large dense-core vesicles (LDCVs): also present; contain peptides (CGRP, substance P) with trophic roles.", "Smooth ER: minimal; all ACh synthesis occurs in cytoplasm using locally supplied precursors.", ],"Source: Miller's Anesthesia 10e, Chapter 11"); } // ── SLIDE 12 — Active Zones { const s=pres.addSlide(); bullets(s,"Active Zones — The Release Sites",[ "Electron-dense thickenings of presynaptic membrane precisely opposite junctional fold crests.", "~200–300 active zones per NMJ terminal bouton.", "Scaffolding proteins: ELKS, Bassoon, Piccolo, RIM1/2, Munc13 organize the AZ matrix.", "RIM proteins tether vesicles and recruit Cav2.1 channels to within nanometers of docked vesicles.", "Close proximity of Ca²⁺ channels and vesicles creates a high-[Ca²⁺] microdomain (>100 µM) on channel opening.", "This nanodomain coupling allows ACh release within <1 ms of action potential arrival.", "AZ spacing matches junctional fold spacing — ensures each quantum released directly over a receptor-rich fold crest.", "AZ disruption (Lambert-Eaton antibodies target Cav2.1; VGCC disorders) reduces quantal content.", ],"Source: Miller's Anesthesia 10e"); } // ── SLIDE 13 — Synaptic Cleft & Basal Lamina { const s=pres.addSlide(); bullets(s,"Synaptic Cleft & Basal Lamina",[ "Synaptic cleft width: ~50–70 nm — narrow enough for rapid ACh diffusion (<0.1 ms).", "Basal lamina fills cleft: laminin, agrin, perlecan, nidogen, collagen IV.", "Agrin (secreted by motor neuron): binds LRP4 → activates MuSK → nAChR clustering.", "AChE: anchored to basal lamina via ColQ collagenic tail; ~3000 active sites/µm².", "AChE hydrolyzes ACh within ~50 µs — prevents receptor desensitization from prolonged exposure.", "Neuregulin-1 (NRG1/ErbB): basal lamina protein; maintains NMJ integrity; regulates AChR expression.", "Basal lamina persists after muscle degeneration → serves as a scaffold guiding regenerating axons back to original NMJ sites.", "ColQ mutations → congenital AChE deficiency → persistent ACh in cleft → slow-channel-like phenotype.", ]); } // ── SLIDE 14 — Postsynaptic Membrane { const s=pres.addSlide(); bullets(s,"Postsynaptic Membrane — The Motor Endplate",[ "Motor endplate: thickened, specialized region of sarcolemma, ~50–100 µm diameter.", "Junctional folds: deep invaginations of the sarcolemma, 0.5–1.0 µm deep — amplify surface area ~10×.", "Fold crests: densely packed nAChRs (~10,000/µm²); face active zones directly.", "Fold troughs: high density of voltage-gated Na⁺ channels (Nav1.4) — generate the muscle AP.", "Spatial separation of nAChRs (crests) and Nav1.4 (troughs) is functionally important for signal amplification.", "Rapsyn: scaffold protein (43 kDa) anchors nAChRs to the cytoskeleton; 1:1 stoichiometry with nAChR.", "Dystrophin-glycoprotein complex (DGC): links actin cytoskeleton to basal lamina — structural integrity.", "MuSK: receptor tyrosine kinase; required for NMJ formation and nAChR clustering (together with LRP4).", ]); } // ── SLIDE 15 — Section 04 { const s=pres.addSlide(); sectionDivider(s,"Acetylcholine Synthesis & Storage","04"); } // ── SLIDE 16 — ACh Synthesis { const s=pres.addSlide(); bullets(s,"Acetylcholine Synthesis",[ "Reaction: Choline + Acetyl-CoA → Acetylcholine + CoA (catalyzed by ChAT).", "Enzyme: Choline acetyltransferase (ChAT) — synthesized in motor neuron cell body; transported to terminal.", "Choline source #1: recycled from AChE hydrolysis of ACh (~50% of choline used).", "Choline source #2: plasma choline uptake via high-affinity Na⁺-coupled choline transporter (CHT1 / SLC5A7).", "Acetyl-CoA source: mitochondrial oxidative phosphorylation (pyruvate → acetyl-CoA).", "ACh synthesis rate is very high — supports rapid vesicle refilling during sustained stimulation.", "Rate-limiting under high demand: CHT1 choline uptake capacity (not ChAT enzyme activity per se).", "ChAT mutations → presynaptic congenital myasthenic syndrome with episodic apnea.", ],"Source: Ganong's 26e; Katzung Pharmacology 16e"); } // ── SLIDE 17 — ACh Storage { const s=pres.addSlide(); bullets(s,"Acetylcholine Storage — Synaptic Vesicles",[ "Newly synthesized ACh is actively packaged into synaptic vesicles.", "Transporter: vesicular ACh transporter (VAChT) — H⁺-antiporter; uses proton gradient maintained by V-ATPase.", "Vesicle interior pH ~5.5 (acidic); high ACh concentration (~200 mM inside vesicle).", "Each vesicle contains one quantum: ~5,000–10,000 ACh molecules.", "Spontaneous random vesicle fusion at rest → miniature endplate potentials (MEPPs): ~0.5 mV.", "MEPP frequency ~1–2/sec per endplate under resting conditions.", "Co-stored with ACh: ATP (purinergic cotransmitter) and low-Mr proteoglycans.", "Vesicle membrane proteins: synaptophysin (glycoprotein marker), synaptotagmin-1 (Ca²⁺ sensor), synapsin (cytoskeletal anchor).", ],"Source: Miller's Anesthesia 10e; Ganong's 26e"); } // ── SLIDE 18 — Section 05 { const s=pres.addSlide(); sectionDivider(s,"Vesicle Pools & Mobilization","05"); } // ── SLIDE 19 — VP1 & VP2 { const s=pres.addSlide(); twoCol(s,"Two Vesicle Pools: VP1 (Reserve) & VP2 (Readily Releasable)", [ "VP1 = Reserve Pool", "Constitutes majority (~80–90%) of all terminal vesicles", "Tethered to actin cytoskeleton by synapsin proteins", "Also anchored by synaptotagmin and spectrin", "Located deep within the nerve terminal", "Mobilized only during intense/prolonged stimulation", "CaMKII phosphorylates synapsin → releases VP1 tether", "Ensures sustained transmission under fatigue conditions", ],[ "VP2 = Readily Releasable Pool (RRP)", "~50–200 vesicles per bouton", "Located immediately adjacent to active zones", "Already docked; primed for Ca²⁺-triggered release", "Released during each action potential", "Depleted rapidly during tetanic stimulation", "Replenished from VP1 (mobilization)", "Determines short-term synaptic plasticity", ],"VP1: Reserve Pool","VP2: Readily Releasable Pool"); } // ── SLIDE 20 — Mobilization { const s=pres.addSlide(); bullets(s,"Vesicle Mobilization & ACh Replenishment",[ "Mobilization = all steps maintaining the terminal's capacity to sustain ACh release.", "Encompasses: choline uptake → ACh synthesis → vesicle filling (VAChT) → transport to active zones.", "During tetanic stimulation: Ca²⁺ accumulates → activates CaMKII → phosphorylates synapsin I.", "Phosphorylated synapsin releases VP1 vesicles from actin tether → vesicles move to active zone.", "Posttetanic potentiation (PTP): residual Ca²⁺ in terminal after tetanus → enhanced ACh release per impulse.", "→ Clinical: posttetanic facilitation in patients under NDMR blockade (TOF count transiently improves after tetanic stimulus).", "Hemicholinium-3 (HC-3): blocks CHT1 → progressive depletion of ACh stores → progressive weakness.", "Mobilization rate is the key determinant of whether NMJ can sustain high-frequency firing.", ],"Source: Miller's Anesthesia 10e"); } // ── SLIDE 21 — Section 06 { const s=pres.addSlide(); sectionDivider(s,"SNARE Proteins & Exocytosis","06"); } // ── SLIDE 22 — SNARE Overview { const s=pres.addSlide(); boxes(s,"SNARE Protein Complex — Key Players",[ {title:"Synaptobrevin / VAMP-2",text:"v-SNARE on vesicle membrane. Coils around t-SNAREs to drive bilayer fusion. Cleaved by BoNT/B and tetanus toxin.",color:"E3F2FD"}, {title:"Syntaxin-1",text:"t-SNARE on plasma membrane. Interacts with Munc18. Cleaved by BoNT/C1.",color:"E8F5E9"}, {title:"SNAP-25",text:"t-SNARE; two SNARE motifs on plasma membrane. Cleaved by BoNT/A, C1, E. Critical for vesicle docking and priming.",color:"FFF8E1"}, {title:"Synaptotagmin-1",text:"Ca²⁺ sensor on vesicle. Binds Ca²⁺ via C2A/C2B domains → triggers fusion pore opening. Also localizes vesicles to Ca²⁺ channel nanodomain.",color:"FCE4EC"}, {title:"Munc18 & Munc13",text:"Regulatory proteins. Munc13 primes vesicles (stabilizes open-syntaxin state). Munc18 escorts syntaxin and is essential for any exocytosis.",color:"F3E5F5"}, {title:"NSF / α-SNAP",text:"ATPase disassembles cis-SNARE complexes post-fusion. Recycles SNARE proteins for subsequent rounds of exocytosis. ATP-dependent.",color:"E0F7FA"}, ]); } // ── SLIDE 23 — Exocytosis Steps { const s=pres.addSlide(); bullets(s,"Process of Exocytosis — Sequential Steps",[ "Step 1 — Tethering: Rab3A-RIM interaction captures vesicle near active zone (~100 nm).", "Step 2 — Docking: synaptobrevin makes initial partial contact with syntaxin/SNAP-25 complex.", "Step 3 — Priming: full SNARE ternary complex assembles (Munc13 facilitates); vesicle fusion-competent.", "Step 4 — Ca²⁺ triggering: action potential → Ca²⁺ enters via Cav2.1 → synaptotagmin-1 binds Ca²⁺.", "Step 5 — Fusion pore: synaptotagmin removes electrostatic clamp on SNARE complex → membranes merge.", "Step 6 — ACh release: ACh floods synaptic cleft within <0.5 ms of Ca²⁺ entry.", "Step 7 — Vesicle retrieval: kiss-and-run (fast), clathrin-mediated endocytosis, or stranded modes.", "One action potential releases ~60–100 quanta simultaneously across all active zones of one bouton.", ],"Source: Miller's Anesthesia 10e"); } // ── SLIDE 24 — Botulinum Toxin & SNARE { const s=pres.addSlide(); table(s,"Botulinum Toxin — SNARE Protein Targets", ["Toxin","Target SNARE","Effect","Clinical Use"], [ ["BoNT/A","SNAP-25 (Gln197-Arg198)","Blocks ACh release → flaccid paralysis","Cosmetic (Botox), spasticity, dystonias, hyperhidrosis"], ["BoNT/B","Synaptobrevin-2 (Gln76-Phe77)","Blocks ACh release","Cervical dystonia (Myobloc)"], ["BoNT/C1","Syntaxin-1 & SNAP-25","Blocks ACh release","Not approved; experimental"], ["BoNT/E","SNAP-25 (Arg180-Ile181)","Blocks ACh release","Infant botulism; food poisoning"], ["Tetanus toxin","Synaptobrevin-2","Retrograde to spinal inhibitory neurons → spastic paralysis","Wound infection; treat with antitoxin"], ] ); } // ── SLIDE 25 — Section 07 { const s=pres.addSlide(); sectionDivider(s,"Calcium in Neuromuscular Transmission","07"); } // ── SLIDE 26 — Calcium Entry { const s=pres.addSlide(); bullets(s,"Calcium Channels & Quantal Release",[ "Primary channel: P/Q-type (Cav2.1) — exclusively at presynaptic active zones.", "Action potential → membrane depolarizes → Cav2.1 opens within ~0.1–0.2 ms.", "Local [Ca²⁺] rises from ~100 nM (resting) to ~100–300 µM at release site microdomain.", "Quantal content ∝ [Ca²⁺]⁴ — highly cooperative; tiny changes in Ca²⁺ have huge effects.", "Doubling extracellular Ca²⁺ → ~16-fold increase in ACh release.", "K⁺ channels (Kv + BK) limit Ca²⁺ entry by repolarizing the terminal rapidly.", "Mg²⁺ competes with Ca²⁺ at P channels → reduces ACh release (clinically relevant in preeclampsia Mg therapy).", "L-type (Cav1) channels NOT involved in NMJ ACh release → dihydropyridine Ca²⁺ blockers do NOT block NMJ.", ],"Source: Miller's Anesthesia 10e"); } // ── SLIDE 27 — Calcium Disorders { const s=pres.addSlide(); bullets(s,"Calcium Channel Disorders & Clinical Relevance",[ "Lambert-Eaton Myasthenic Syndrome: IgG autoantibodies target Cav2.1 → reduced Ca²⁺ entry → reduced ACh release.", "→ Proximal muscle weakness, autonomic dysfunction, diminished reflexes.", "→ Strength IMPROVES with repetitive stimulation (Ca²⁺ accumulates) — opposite to MG.", "→ EMG: low resting CMAP amplitude; >100% increment at 50 Hz stimulation.", "Hypermagnesemia: competitively blocks Cav2.1 → potentiates NDMRs; cause: MgSO₄ for eclampsia.", "4-Aminopyridine (4-AP, dalfampridine): blocks voltage-gated K⁺ channels → prolongs depolarization → more Ca²⁺ entry → ↑ ACh release.", "Posttetanic potentiation (PTP): Ca²⁺ accumulates in terminal during tetanic stimulation → transient increase in quantal content.", "ω-Conotoxin GVIA (N-type blocker) and ω-Agatoxin IVA (P/Q-type blocker): research tools to define channel roles.", ],"Source: Miller's Anesthesia 10e; Bradley & Daroff Neurology"); } // ── SLIDE 28 — Section 08 { const s=pres.addSlide(); sectionDivider(s,"Nicotinic Acetylcholine Receptor (nAChR)","08"); } // ── SLIDE 29 — nAChR Structure { const s=pres.addSlide(); bullets(s,"nAChR — Molecular Structure",[ "Pentameric ligand-gated ion channel: 5 subunits arranged symmetrically around a central aqueous pore.", "Adult (mature) receptor: α1₂β1δε — two α, one β, one δ, one ε subunit.", "Fetal / denervated receptor: α1₂β1δγ — γ replaces ε; broader conductance (~50 pS vs 40 pS), longer open time.", "Each subunit: 4 transmembrane domains (TM1–TM4); TM2 from each subunit lines the ion channel pore.", "ACh binding pockets: at α/δ and α/ε interfaces — both must be occupied to open the channel.", "Extracellular domain contains a ligand-binding site with a characteristic 'aromatic cage.'", "Ion channel: non-selective cation channel; Na⁺ in, K⁺ out (net Na⁺ influx dominates).", "Single-channel conductance: 40–50 pS; mean open time ~1 ms at 37°C.", ],"Source: Katzung Pharmacology 16e; Goodman & Gilman"); } // ── SLIDE 30 — nAChR Activation & Ion Flow { const s=pres.addSlide(); bullets(s,"nAChR Activation & Ion Flow",[ "Two ACh molecules bind → simultaneous conformational change in all 5 subunits → channel opens.", "Na⁺ influx (dominant) + K⁺ efflux → net inward current → membrane depolarization.", "Single-channel current ~4 nA produces a miniature endplate current (MEPC).", "Endplate potential (EPP): summated response from ~200–400 channel openings per quantum.", "EPP amplitude: ~40–70 mV above resting membrane potential (-90 mV → approximately -25 to -50 mV peak).", "This EPP exceeds threshold (-55 mV) for Nav1.4 activation → muscle action potential propagates bidirectionally.", "Safety factor: EPP is 3–4× larger than minimally required — buffers against partial receptor loss.", "ACh rapidly dissociates from nAChR after channel opening → hydrolyzed by AChE (prevents persistent activation).", ],"Source: Ganong's 26e"); } // ── SLIDE 31 — Receptor States { const s=pres.addSlide(); boxes(s,"nAChR Functional States",[ {title:"Resting (Closed)",text:"No ACh bound. Channel closed. Low ACh affinity. Predominant state at -90 mV resting potential. Most nAChRs exist in this state.",color:"E8F5E9"}, {title:"Activated (Open)",text:"Two ACh molecules bound. Channel open ~1 ms. Na⁺ influx → EPP. Transitions back to resting or desensitized state.",color:"E3F2FD"}, {title:"Desensitized",text:"ACh bound but channel closed. High ACh affinity. Prolonged agonist exposure. Succinylcholine Phase II block. Recovery slow (seconds to minutes).",color:"FCE4EC"}, {title:"Non-Depolarizing Block",text:"Competitive antagonists (rocuronium, tubocurarine) occupy ACh binding sites on α subunits. No channel opening. Reversed by ↑ACh (neostigmine) or direct removal (sugammadex).",color:"FFF8E1"}, ]); } // ── SLIDE 32 — Section 09 { const s=pres.addSlide(); sectionDivider(s,"Endplate Potential, Safety Factor & MEPPs","09"); } // ── SLIDE 33 — Transmission Sequence { const s=pres.addSlide(); bullets(s,"From Nerve Impulse to Muscle Contraction — Full Sequence",[ "1. Motor nerve action potential (Aα fiber, ~90 mV, 1 ms duration) propagates to terminal.", "2. Cav2.1 channels open → Ca²⁺ influx → SNARE complex activated → ACh released (~60 quanta).", "3. ACh diffuses across 50–70 nm cleft (< 0.1 ms) → binds nAChRs at fold crests.", "4. nAChR channels open → Na⁺ influx → endplate potential (EPP) ~40–70 mV.", "5. EPP spreads electrotonically → reaches threshold at fold troughs → Nav1.4 channels fire.", "6. Muscle action potential propagates along sarcolemma and down T-tubules.", "7. T-tubule depolarization → Cav1.1 (DHPR) senses voltage → activates RyR1 on SR.", "8. Ca²⁺ released from SR binds troponin C → conformational change → actin-myosin cross-bridge cycling → contraction.", ],"Source: Ganong's 26e; Miller's Anesthesia 10e"); } // ── SLIDE 34 — Safety Factor { const s=pres.addSlide(); bullets(s,"Safety Factor of Neuromuscular Transmission",[ "Safety factor = margin by which EPP exceeds threshold for muscle AP generation.", "Normal EPP: ~70 mV depolarization; threshold: ~35 mV above resting → safety factor ~2×.", "Consequence: up to ~50% reduction in ACh release before transmission failure occurs.", "In myasthenia gravis: ~70–80% nAChR loss needed before clinical weakness appears.", "Non-depolarizing NMBDs: require ~75–80% receptor occupancy before visible neuromuscular block.", "Factors reducing safety factor: MG, LEMS, elevated Mg²⁺, low Ca²⁺, acidosis, hypothermia, aminoglycosides.", "Train-of-four (TOF) ratio ≥ 0.9 confirms safety factor adequate for extubation.", "Volatile anesthetics: reduce safety factor by decreasing ACh release and postsynaptic sensitivity.", ],"Source: Miller's Anesthesia 10e; Ganong's 26e"); } // ── SLIDE 35 — MEPPs { const s=pres.addSlide(); bullets(s,"Miniature Endplate Potentials (MEPPs)",[ "Spontaneous fusion of single vesicles at rest → MEPPs at ~1–2 per second per endplate.", "Amplitude: ~0.5 mV; duration ~5–10 ms — too small to trigger a muscle AP.", "First described by Fatt & Katz (1952) using intracellular microelectrodes.", "Key evidence for quantal hypothesis: ACh is released in discrete packets (quanta).", "MEPP amplitude ∝ number of ACh molecules per vesicle (quantum size).", "Reduced MEPP frequency: botulinum toxin (SNARE cleavage), Lambert-Eaton syndrome (↓ Ca²⁺ entry).", "Reduced MEPP amplitude: myasthenia gravis (fewer functional nAChRs per quantum).", "Increased MEPP frequency: alpha-latrotoxin (black widow venom) — massive vesicle exocytosis.", ],"Source: Ganong's 26e"); } // ── SLIDE 36 — Section 10 { const s=pres.addSlide(); sectionDivider(s,"AChE, Choline Recycling & Metabolism","10"); } // ── SLIDE 37 — AChE { const s=pres.addSlide(); bullets(s,"Acetylcholinesterase (AChE) — Structure & Function",[ "One of the fastest enzymes known: ~25,000 ACh molecules hydrolyzed per second per active site.", "Anchored in synaptic basal lamina via ColQ tail; density ~3000 active sites/µm² in cleft.", "Molecular form at NMJ: asymmetric A12 form (12 catalytic subunits + ColQ structural anchor).", "Active site: serine esterase with catalytic triad — Ser203, His447, Glu334.", "Reaction: ACh + H₂O → choline + acetic acid (acetate).", "ACh hydrolysis within ~50 µs of receptor binding — terminates signal, prevents desensitization.", "Products: acetate enters metabolic pool; choline recycled via CHT1 for re-synthesis.", "AChE inhibitors (neostigmine, organophosphates) prolong ACh action — increase EPP amplitude.", ],"Source: Miller's Anesthesia 10e; Goodman & Gilman"); } // ── SLIDE 38 — AChE Inhibitors { const s=pres.addSlide(); table(s,"AChE Inhibitors — Clinical Overview", ["Drug","Mechanism","Duration","Clinical Use"], [ ["Neostigmine","Reversible carbamate; carbamylates Ser203","30–60 min","Reversal of NDMR block; MG treatment"], ["Pyridostigmine","Reversible carbamate; similar to neostigmine","3–6 hours","Chronic MG oral treatment"], ["Edrophonium","Reversible; electrostatic + H-bond to AChE","5–15 min","Tensilon test for MG diagnosis"], ["Physostigmine","Reversible carbamate; tertiary amine (BBB+)","1–2 hours","Central anticholinergic syndrome, atropine toxicity"], ["Organophosphates","Irreversible; phosphorylate Ser203 permanently","Days–weeks","Nerve agent poisoning; treat with pralidoxime + atropine"], ["Rivastigmine","Pseudo-irreversible carbamate; CNS selective","6–12 hours","Alzheimer disease (CNS AChE inhibitor)"], ] ); } // ── SLIDE 39 — Choline Recycling & Metabolism { const s=pres.addSlide(); bullets(s,"Choline Recycling & NMJ Energy Metabolism",[ "After ACh hydrolysis → choline released into cleft → recaptured by CHT1 on presynaptic membrane.", "CHT1 (SLC5A7): high-affinity, Na⁺-coupled; uptake is rate-limiting during intense firing.", "~50% of released choline is recycled; remainder comes from plasma (diet, phospholipid catabolism).", "Energy at the NMJ: very high metabolic demands → dense mitochondria (~50% of terminal volume).", "ATP consumed by: Na⁺/K⁺-ATPase (restoring ion gradients), V-ATPase (vesicle proton pump), actin dynamics.", "Acetyl-CoA production: pyruvate dehydrogenase in mitochondria → acetyl-CoA + CO₂ + NADH.", "Metabolic acidosis: reduces EPP amplitude; hypoxia impairs vesicle refilling and choline uptake.", "Hypothermia: slows ChAT, CHT1, and AChE activities → prolongs NMJ block under anesthesia.", ],"Source: Miller's Anesthesia 10e; Ganong's 26e"); } // ── SLIDE 40 — Vesicle Recycling { const s=pres.addSlide(); bullets(s,"Synaptic Vesicle Recycling Pathways",[ "After exocytosis, vesicle membrane must be retrieved to prevent terminal membrane expansion.", "Kiss-and-run: transient fusion pore; vesicle retains shape → rapid recycling (<1 sec); quantum may be partial.", "Compensatory (clathrin-mediated) endocytosis: full fusion; clathrin-AP2 coat forms at periactive zone; dynamin pinches off ~60–90 sec.", "Stranded: complete collapse into plasma membrane; retrieved only after next stimulus; slower.", "Activity-dependent bulk endocytosis (ADBE): large membrane invaginations at high stimulation rate; clathrin-independent.", "Retrieved membranes sorted in early endosome → pinch off new vesicles → refilled via VAChT → join VP1 reserve pool.", "Clathrin machinery proteins: AP-2, AP180, epsin, synaptojanin, amphiphysin, dynamin.", "Synaptojanin (phosphoinositide phosphatase) essential for clathrin uncoating → loss → vesicle recycling failure.", ],"Source: Miller's Anesthesia 10e"); } // ── SLIDE 41 — Section 11 { const s=pres.addSlide(); sectionDivider(s,"NMJ Development & Maintenance","11"); } // ── SLIDE 42 — NMJ Development { const s=pres.addSlide(); bullets(s,"NMJ Development — Key Steps",[ "Pre-pattern: before innervation, MuSK (activated by Dok-7) clusters nAChRs in the future endplate zone.", "Innervation: motor axon guided to endplate zone by netrin, ephrin, semaphorin gradients.", "Agrin secretion: motor neuron releases agrin into basal lamina.", "LRP4-MuSK signaling: agrin binds LRP4 → LRP4-MuSK complex dimerizes → MuSK autophosphorylation.", "Rapsyn recruitment: MuSK signaling recruits rapsyn → rapsyn stabilizes nAChR clusters at junctional folds.", "Synaptic competition: multiple axons initially innervate each fiber → activity-dependent pruning retains strongest one.", "Maturation: γ→ε subunit switch (fetal→adult nAChR); junctional folds deepen; AZ number increases.", "ErbB2/ErbB4 (neuregulin receptors on muscle): regulate nAChR subunit expression and NMJ stability.", ]); } // ── SLIDE 43 — NMJ Plasticity & Aging { const s=pres.addSlide(); bullets(s,"NMJ Maintenance, Plasticity & Aging",[ "Adult NMJ requires continuous trophic support from motor neuron (neuregulin-1/ErbB, BDNF, GDNF).", "Denervation → within 24–48 hr: muscle upregulates fetal γ-nAChRs across entire sarcolemma.", "→ Succinylcholine in denervated / burned / prolonged-immobility patients: massive K⁺ efflux → life-threatening hyperkalemia.", "→ Succinylcholine contraindicated >48 hr after acute denervation, burns, major trauma, prolonged immobility.", "Exercise: enlarges NMJ; increases active zone number and vesicle pool size → greater safety factor.", "Disuse atrophy: NMJ shrinks; junctional folds simplify; safety factor reduced.", "Aging: NMJ fragmentation; active zone loss; reduced quantal content → contributes to sarcopenia.", "Reinnervation: motor axon regrows along original basal lamina channels to original endplate site.", ]); } // ── SLIDE 44 — Section 12 { const s=pres.addSlide(); sectionDivider(s,"Neuromuscular Blocking Drugs (NMBDs)","12"); } // ── SLIDE 45 — NMBD Overview { const s=pres.addSlide(); twoCol(s,"NMBDs — Depolarizing vs Non-Depolarizing", [ "DEPOLARIZING NMBDs", "Only agent: succinylcholine (suxamethonium)", "Mimics ACh → persistent sarcolemma depolarization", "Phase I: fasciculations → flaccid paralysis", "Phase II: receptor desensitization (>5 mg/kg, infusion)", "Metabolism: plasma pseudocholinesterase", "NOT reversed by neostigmine in Phase I", "Contraindicated: denervation, burns, myopathies", "Risks: MH trigger, hyperkalemia, bradycardia", ],[ "NON-DEPOLARIZING NMBDs", "Competitive antagonists at nAChR α subunits", "Examples: rocuronium, vecuronium, atracurium, cisatracurium, pancuronium", "No fasciculations; smooth paralysis onset", "Reversed by neostigmine+glycopyrrolate or sugammadex", "Sugammadex encapsulates rocuronium/vecuronium", "TOF monitored: TOF ratio ≥0.9 for full recovery", "Potentiated by: volatile agents, Mg²⁺, acidosis, hypothermia, aminoglycosides", ],"Depolarizing","Non-Depolarizing"); } // ── SLIDE 46 — NDMR Comparison Table { const s=pres.addSlide(); table(s,"Non-Depolarizing NMBDs — Comparison", ["Drug","Onset","Duration","Elimination","Key Notes"], [ ["Rocuronium","1–2 min","Intermediate (30–60 min)","Hepatic/biliary","Fastest onset NDMR; fully reversed by sugammadex"], ["Vecuronium","2–3 min","Intermediate (25–40 min)","Hepatic/biliary","Cardiovascular neutral; liver accumulation"], ["Cisatracurium","3–5 min","Intermediate (40–60 min)","Hofmann elimination","Organ-independent; preferred ICU agent"], ["Atracurium","2–3 min","Intermediate (30–45 min)","Hofmann + plasma ester","Histamine release possible at high doses"], ["Pancuronium","3–4 min","Long (60–90 min)","Renal/hepatic","Vagolytic tachycardia; avoid in cardiac disease"], ["Mivacurium","2–3 min","Short (15–20 min)","Plasma cholinesterase","Short-acting; prolonged in pseudocholinesterase deficiency"], ] ); } // ── SLIDE 47 — NMJ Monitoring { const s=pres.addSlide(); bullets(s,"Monitoring Neuromuscular Blockade",[ "Peripheral nerve stimulator (PNS): applied over ulnar nerve; monitor adductor pollicis muscle.", "Train-of-Four (TOF): 4 stimuli at 2 Hz; TOF ratio = T4/T1 amplitude.", "→ TOF count 0: profound/complete block.", "→ TOF count 1–3: deep-moderate block.", "→ TOF ratio <0.9: residual block (risk of aspiration/airway compromise at extubation).", "→ TOF ratio ≥0.9: adequate recovery — current recommended threshold for extubation.", "Post-tetanic count (PTC): assesses depth when TOF count = 0; low PTC = very deep block.", "Double-burst stimulation (DBS): more sensitive than TOF for detecting residual block subjectively.", "Quantitative monitoring (acceleromyography/electromyography) superior to tactile/visual assessment.", ],"Source: Miller's Anesthesia 10e"); } // ── SLIDE 48 — Section 13 { const s=pres.addSlide(); sectionDivider(s,"NMJ Disorders — Clinical Correlates","13"); } // ── SLIDE 49 — Myasthenia Gravis { const s=pres.addSlide(); bullets(s,"Myasthenia Gravis (MG)",[ "Autoimmune disorder: IgG antibodies target postsynaptic nAChRs (~85%), MuSK (~10%), LRP4 (~2%).", "Anti-nAChR IgG causes: receptor internalization/degradation, complement-mediated destruction, direct functional block.", "Pathology: reduced nAChR density; simplified junctional folds; widened cleft — decreased EPP amplitude.", "Hallmark: fatigable weakness — worsens with repetitive use, improves with rest.", "Ocular onset most common (ptosis, diplopia); may progress to bulbar and limb weakness; respiratory crisis possible.", "EMG: decremental response at 3 Hz repetitive stimulation (>10% decrement).", "Diagnosis: anti-AChR/MuSK antibodies; positive edrophonium (Tensilon) test; CT chest (thymoma in 10–15%).", "Treatment: pyridostigmine (symptomatic), corticosteroids/azathioprine/mycophenolate (immunosuppression), thymectomy, IVIg/plasmapheresis for crisis.", ],"Source: Ganong's 26e; Bradley & Daroff Neurology"); } // ── SLIDE 50 — Lambert-Eaton Syndrome { const s=pres.addSlide(); bullets(s,"Lambert-Eaton Myasthenic Syndrome (LEMS)",[ "Presynaptic NMJ disorder: IgG autoantibodies against voltage-gated Ca²⁺ channels (Cav2.1, P/Q-type).", "50–60% are paraneoplastic — small-cell lung carcinoma most common.", "Mechanism: antibodies reduce Cav2.1 density at active zones → less Ca²⁺ entry → reduced quantal release.", "Weakness: proximal lower-limb predominance; autonomic features (dry mouth, constipation, impotence).", "Reflexes: diminished at rest but TRANSIENTLY restored after brief exercise.", "Hallmark: incremental response (>100%) on 50 Hz repetitive stimulation (Ca²⁺ accumulates).", "Diagnosis: anti-Cav2.1 antibodies; EMG incremental pattern; CT/PET for occult malignancy.", "Treatment: 3,4-diaminopyridine (3,4-DAP) — blocks K⁺ channels → prolongs depolarization → ↑ ACh release; IVIg; treat malignancy.", ],"Source: Bradley & Daroff Neurology; Miller's Anesthesia 10e"); } // ── SLIDE 51 — CMS Table { const s=pres.addSlide(); table(s,"Congenital Myasthenic Syndromes (CMS)", ["Type","Defective Protein","Pathophysiology","Hallmark"], [ ["Presynaptic","ChAT","Reduced ACh synthesis","Episodic apnea; worse with fever"], ["Slow-channel CMS","nAChR α/β/δ/ε (GoF)","Prolonged channel opening → Ca²⁺ overload","Progressive focal weakness; worsened by AChEIs"], ["Fast-channel CMS","nAChR α/δ/ε (LoF)","Short channel open time → small EPP","Similar to seronegative MG"], ["Rapsyn deficiency","Rapsyn scaffold","Poor nAChR clustering at endplate","Neonatal hypotonia, ptosis, apnea"], ["MuSK CMS","MuSK kinase","Impaired agrin→MuSK signaling","Bulbar weakness; variable severity"], ["ColQ/AChE deficiency","ColQ tail protein","AChE absent from cleft → excess depolarization","Worsened by pyridostigmine (contraindicated)"], ] ); } // ── SLIDE 52 — Botulism & Other Toxins { const s=pres.addSlide(); bullets(s,"Botulism — Presynaptic NMJ Poisoning",[ "Clostridium botulinum produces neurotoxin types A–G — all block NMJ transmission via SNARE cleavage.", "Mechanism: BoNT heavy chain binds polysialogangliosides + synaptotagmin → endocytosed into vesicle.", "BoNT light chain escapes → zinc endopeptidase cleaves SNARE protein → ACh release completely blocked.", "Clinical: descending flaccid paralysis, bilateral cranial nerve palsies, autonomic dysfunction.", "Foodborne botulism (pre-formed toxin), wound botulism (germination), infant botulism (honey/spore ingestion).", "Treatment: heptavalent antitoxin (HBAT) — most effective within 24–48 hr of symptom onset; supportive care; mechanical ventilation.", "Therapeutic BoNT/A (Botox, Dysport): focal injection → localized presynaptic blockade → reduces overactive muscle contractions.", "Therapeutic applications: cervical dystonia, blepharospasm, spasticity, hyperhidrosis, cosmetic wrinkles, chronic migraine.", ],"Source: Miller's Anesthesia 10e"); } // ── SLIDE 53 — Other NMJ Diseases { const s=pres.addSlide(); boxes(s,"Other Conditions Affecting the NMJ",[ {title:"Organophosphate Poisoning",text:"Irreversible AChE inhibition → excess ACh → continuous muscle depolarization → fasciculations, SLUDGE, respiratory failure. Treat: atropine + pralidoxime (within hours).",color:"FCE4EC"}, {title:"Hypermagnesemia",text:"Mg²⁺ blocks Cav2.1 channels → reduces ACh quantal content. Also reduces postsynaptic sensitivity. Potentiates NDMRs. Occurs with MgSO₄ for eclampsia.",color:"E3F2FD"}, {title:"Aminoglycoside Antibiotics",text:"Block presynaptic Ca²⁺ channels (↓ ACh release) AND reduce postsynaptic nAChR sensitivity. Potentiate NDMRs. Avoid in MG patients.",color:"E8F5E9"}, {title:"Black Widow Venom (α-Latrotoxin)",text:"Binds presynaptic receptor → massive vesicle exocytosis → initial excitatory phase → transmitter depletion → weakness.",color:"FFF8E1"}, ]); } // ── SLIDE 54 — Section 14 { const s=pres.addSlide(); sectionDivider(s,"Drug Targets at the NMJ — Full Summary","14"); } // ── SLIDE 55 — Full Drug Target Table { const s=pres.addSlide(); table(s,"Drug Targets at the NMJ", ["Target","Drug / Toxin","Effect"], [ ["CHT1 (choline transport)","Hemicholinium-3","Blocks choline uptake → depletes ACh stores"], ["VAChT (vesicle loading)","Vesamicol","Blocks VAChT → prevents ACh packaging"], ["ChAT (ACh synthesis)","ChAT gene mutations (CMS)","Reduced ACh synthesis → episodic weakness"], ["Cav2.1 channels","Mg²⁺, ω-Agatoxin IVA, LEMS antibodies","↓ Ca²⁺ entry → reduced ACh quantal release"], ["SNARE proteins (exocytosis)","Botulinum toxins A–G","SNARE cleavage → complete ACh release block"], ["Vesicle exocytosis","α-Latrotoxin (black widow)","Massive ACh release → depletion → weakness"], ["nAChR (competitive antagonism)","Rocuronium, tubocurarine, pancuronium","Competitive block → no EPP"], ["nAChR (depolarizing)","Succinylcholine","Persistent depolarization → desensitization block"], ["AChE","Neostigmine, organophosphates","Inhibit ACh hydrolysis → ↑ ACh in cleft"], ["K⁺ channels","4-Aminopyridine (4-AP)","Prolongs depolarization → ↑ Ca²⁺ → ↑ ACh release (treats LEMS)"], ] ); } // ── SLIDE 56 — Section 15 — Summary { const s=pres.addSlide(); sectionDivider(s,"Summary & Key Points","15"); } // ── SLIDE 57 — Key Points Part 1 { const s=pres.addSlide(); bullets(s,"Key Summary Points — Part 1",[ "NMJ = specialized synapse converting nerve AP to muscle contraction via ACh neurotransmission.", "Three structural zones: presynaptic terminal (bouton), synaptic cleft (50–70 nm), postsynaptic endplate.", "ACh synthesized from choline + acetyl-CoA (ChAT) in the presynaptic cytoplasm; stored in vesicles (~10,000 molecules each).", "Two vesicle pools: VP1 (reserve, cytoskeletal tether) and VP2 (readily releasable, at active zones).", "Exocytosis: Ca²⁺ via Cav2.1 → synaptotagmin-1 senses Ca²⁺ → SNARE ternary complex → fusion pore → ACh release.", "Quantal content: ~60 quanta per AP; each quantum = ~10,000 ACh molecules.", "nAChR: pentameric (α1₂β1δε); dual ACh binding required; Na⁺ influx → EPP.", "Safety factor: EPP greatly exceeds threshold → highly reliable 1:1 coupling in health.", ]); } // ── SLIDE 58 — Key Points Part 2 { const s=pres.addSlide(); bullets(s,"Key Summary Points — Part 2",[ "AChE (anchored in basal lamina): hydrolyzes ACh in ~50 µs; prevents receptor desensitization.", "Choline recycled by CHT1 → rate-limiting for ACh resynthesis at high firing frequencies.", "NMJ development requires agrin-LRP4-MuSK-rapsyn signaling for nAChR clustering.", "Denervation → extrajunctional fetal γ-nAChR → hyperkalemia with succinylcholine.", "Myasthenia gravis: postsynaptic (anti-nAChR, anti-MuSK); fatigable weakness; decremental EMG; treat with pyridostigmine + immunosuppression.", "LEMS: presynaptic (anti-Cav2.1); incremental EMG; strength improves with exercise; treat with 3,4-DAP.", "Botulinum toxin: cleaves SNARE proteins → no ACh release → flaccid paralysis; therapeutic applications.", "NDMR monitoring by TOF; full recovery = TOF ratio ≥0.9; reversed by neostigmine or sugammadex.", ]); } // ── SLIDE 59 — Concept Connections (Visual Summary) { const s=pres.addSlide(); boxes(s,"NMJ — Integrated Concept Map",[ {title:"Presynaptic",text:"ACh synthesis (ChAT) → vesicle storage (VAChT) → Ca²⁺-triggered release (Cav2.1 / SNARE) → Mobilization (VP1→VP2 via synapsin phosphorylation).",color:"E3F2FD"}, {title:"Synaptic Cleft",text:"ACh diffuses <0.1 ms. AChE (ColQ-anchored) hydrolyzes ACh in ~50 µs. Choline recycled via CHT1. Basal lamina provides structural scaffold.",color:"E8F5E9"}, {title:"Postsynaptic",text:"nAChR (α₁₂β₁δε): Na⁺ influx → EPP → Nav1.4 → muscle AP → EC coupling → contraction. Safety factor ensures reliability.",color:"FFF8E1"}, {title:"Clinical Relevance",text:"MG: ↓ nAChR. LEMS: ↓ Ca²⁺ channels. BoNT: ↓ SNARE. AChEIs: ↑ ACh. NDMRs: block nAChR. Succinylcholine: depolarize nAChR.",color:"FCE4EC"}, ]); } // ── SLIDE 60 — Thank You { const s=pres.addSlide(); s.addShape(pres.ShapeType.rect,{x:0,y:0,w:10,h:5.625,fill:{color:C.navy},line:{color:C.navy}}); s.addShape(pres.ShapeType.rect,{x:0,y:4.4,w:10,h:1.225,fill:{color:C.blue},line:{color:C.blue}}); s.addShape(pres.ShapeType.rect,{x:0,y:0,w:0.35,h:5.625,fill:{color:C.accent},line:{color:C.accent}}); s.addText("Thank You",{x:0.6,y:1.1,w:9,h:1.4,fontSize:44,bold:true,color:C.white,fontFace:"Calibri",align:"left"}); s.addText("Neuromuscular Junction: Anatomy, Physiology & Metabolism",{x:0.6,y:2.55,w:9,h:0.7,fontSize:18,color:"A0BFD8",fontFace:"Calibri",align:"left"}); s.addText("Total slides: 60 | 15 Sections",{x:0.6,y:3.25,w:9,h:0.5,fontSize:14,color:C.white,fontFace:"Calibri",align:"left"}); s.addText("Sources: Ganong's Review of Medical Physiology 26e | Miller's Anesthesia 10e | Katzung's Basic & Clinical Pharmacology 16e | Goodman & Gilman's Pharmacological Basis of Therapeutics",{x:0.6,y:4.55,w:9,h:0.45,fontSize:9.5,color:C.white,italic:true,fontFace:"Calibri",align:"left"}); } // ── WRITE ────────────────────────────────────────────────────────────────────── pres.writeFile({fileName:"/home/daytona/workspace/nmj-ppt/NMJ_Anatomy_Physiology_Metabolism.pptx"}) .then(()=>console.log("Done")) .catch(e=>{console.error(e);process.exit(1);}); ENDOFSCRIPT echo "Written"